secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021239
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma Q1 net loss $27.8M; focuses Alzheimer's trial on 40 mg dose
-------------------------------------------------------------------------

- Net loss $27.8M ($0.73/share) vs $21.0M ($0.56) in Q1 2022; cash $219.9M.
- Phase 2/3 LIFT-AD trial to focus on 40 mg fosgonimeton; 70 mg arm discontinued.
- Open-label extension extended to up to 30 months; >85% enrollment from prior trials.
- ATH-1105 preclinical data in ALS shows prolonged survival and improved motor function; IND-enabling work for 2024 first-in-human.
- End of Phase 2 meeting with FDA scheduled for summer 2023; timeline update expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017023021239/0000950170-23-021239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017023021239/atha-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer